A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors (Q45716342)

15 December 2017

title

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors (English)

1 reference

15 December 2017

Sunil Sharma

1

1 reference

15 December 2017

Joachim Beck

2

1 reference

15 December 2017

Monica Mita

3

1 reference

15 December 2017

Sofia Paul

4

1 reference

15 December 2017

Margaret M Woo

5

1 reference

15 December 2017

Margaret Squier

6

1 reference

15 December 2017

Brian Gadbaw

7

1 reference

15 December 2017

H Miles Prince

8

1 reference

15 December 2017

publication date

2 February 2013

1 reference

Investigational New Drugs

15 December 2017

published in

1 reference

15 December 2017

volume

31

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

974-985

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-9930-2

15 December 2017

exact match

0 references

cites work

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Critical aspects of the Bayesian approach to phase I cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Congenital and acquired long QT syndrome. Current concepts and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9930-2

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)

21 January 2018

1 reference

12 December 2020

Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

1 reference

12 December 2020

10.1007/S10637-013-9930-2

Identifiers

DOI

1 reference

Dimensions Publication ID

15 December 2017

1023271005

0 references

1 reference